CN-122017090-A - Biomarker combination for screening heart failure pleural effusion, application, system, equipment and medium

CN122017090ACN 122017090 ACN122017090 ACN 122017090ACN-122017090-A

Abstract

The invention discloses a biomarker combination for screening heart failure pleural effusion, application, a system, equipment and a medium. The biomarker combination comprises the ratio of the chest-water serum concentration of at least one long-chain acyl carnitine in palmitoyl carnitine, stearoyl carnitine, octadecadienoyl carnitine and octadecenoyl carnitine. The biomarker combination provided by the invention has higher clinical value in screening or auxiliary diagnosis of heart failure pleural effusion.

Inventors

HU ZHIDE
ZHENG WENQI
YAN CHENG
Zha Suna
YAN LI
WEN JIANXUN

Assignees

内蒙古医科大学附属医院(内蒙古自治区心血管研究所)

Dates

Publication Date: 20260512
Application Date: 20260205

Claims (9)

1. A biomarker combination for screening heart failure pleural effusion, which is characterized in that the biomarker combination is selected from at least one of the following (a) - (d): (a) The ratio of the concentration of palmitoyl carnitine in the hydrothorax sample to the concentration of palmitoyl carnitine in the serum sample; (b) The ratio of the concentration of stearoyl carnitine in the hydrothorax sample to the concentration of stearoyl carnitine in the serum sample; (c) The ratio of the concentration of octadecadienoyl carnitine in the hydrothorax sample to the concentration of octadecadienoyl carnitine in the serum sample; (d) Ratio of the concentration of octadecenoyl carnitine in the hydrothorax sample to the concentration of octadecenoyl carnitine in the serum sample.
2. Use of a detection reagent for screening biomarker combinations for heart failure pleural effusion according to claim 1 in the preparation of a product for screening heart failure pleural effusion.
3. The use according to claim 2, wherein the product is a kit for screening heart failure pleural effusion comprising a first detection reagent for detecting palmitoyl carnitine concentration in a hydrothorax sample and a serum sample; And/or a second detection reagent for detecting the concentration of stearoyl carnitine in a hydrothorax sample and a serum sample; And/or a third detection reagent for detecting the concentration of octadecadienoyl carnitine in a hydrothorax sample and a serum sample; And/or a fourth detection reagent for detecting the concentration of octadecenoyl carnitine in a hydrothorax sample and a serum sample.
4. A system for screening for heart failure pleural effusion, comprising: The data acquisition module is used for acquiring the concentrations of long-chain acyl carnitine in a serum sample and a hydrothorax sample, and comprises acquiring the palmitoyl carnitine concentration C pC16 in the hydrothorax sample and the palmitoyl carnitine concentration C sC16 in the serum sample, and/or the stearoyl carnitine concentration C pC18 in the hydrothorax sample and the stearoyl carnitine concentration C sC18 in the serum sample, and/or the stearoyl carnitine concentration C pC18:2 in the hydrothorax sample and the stearoyl carnitine concentration C sC18:2 in the serum sample, and/or the octadecene acyl carnitine concentration C pC18:1 in the hydrothorax sample and the octadecene acyl carnitine concentration C sC18:1 in the serum sample; A calculation module for calculating the ratio of each long-chain acyl carnitine in the hydrothorax sample to each long-chain acyl carnitine in the serum sample, K C16 = C pC16 / C sC16 , and/or K C18 = C pC18 / C sC18 , and/or K C18:2 = C pC18:2 / C sC18:2 , and/or K C18:1 = C pC18:1 / C sC18:1 ; the judging module is used for comparing the ratio obtained by the calculating module with a preset corresponding reference threshold value; and the output module is used for outputting the risk level of the heart failure pleural effusion according to the comparison result of the judging module.
5. The system for screening heart failure pleural effusion of claim 4, wherein the K C16 is greater than a corresponding reference threshold value a C16 , the risk level of heart failure pleural effusion is low, the K C16 is less than a reference threshold value a C16 , the risk level of heart failure pleural effusion is high; the K C18 is larger than a corresponding reference threshold value alpha C18 , and the risk level of heart failure pleural effusion is low, wherein the K C16 is smaller than a reference threshold value alpha C18 , and the risk level of heart failure pleural effusion is high; The K C18:2 is larger than a corresponding reference threshold value alpha C18:2 , and the risk level of heart failure pleural effusion is low, wherein the K C16 is smaller than a reference threshold value alpha C18:2 , and the risk level of heart failure pleural effusion is high; The K C18:1 is larger than the corresponding reference threshold alpha C18:1 , the risk level of heart failure pleural effusion is low, the K C16 is smaller than the reference threshold alpha C18:1 , and the risk level of heart failure pleural effusion is high.
6. The system for screening for heart failure pleural effusions of claim 5, wherein the reference threshold a C16 of K C16 is 0.597, the reference threshold a C18 of K C18 is 0.492, the reference threshold a C18:2 of K C18:2 is 0.443, and the reference threshold a C18:1 of K C18:1 is 0.307.
7. The system for screening for heart failure pleural effusion of claim 4, wherein the serum sample and the pleural fluid sample are from the same subject, and the subject is a pleural effusion patient.
8. An electronic device comprising a memory and a processor, wherein the memory stores a computer program, and wherein the processor, when calling the computer program in the memory, performs the functions of the modules in the system for screening heart failure pleural effusion of claim 4.
9. A storage medium having stored therein a computer program for implementing the functions of the modules of the system for screening for heart failure pleural effusions of claim 4.

Description

Biomarker combination for screening heart failure pleural effusion, application, system, equipment and medium Technical Field The invention belongs to the technical field of biomarker screening, and particularly relates to a biomarker combination for screening heart failure pleural effusion, and application, a system, equipment and a medium thereof. Background Pleural effusion (Pleural effusion, PE) is a common clinical sign of various diseases affecting the pleura, and four common causes of PE are counted as malignant tumor, heart failure, pneumonia and tuberculosis, respectively. In clinical practice, the etiology of misdiagnosed PE often causes unnecessary treatments and examinations, malignant pleural effusions (MALIGNANT PLEURAL EFFUSION, MPE), parapneumonic pleural effusions (Parapneumonic pleural effusion, PPE) and tuberculous pleural effusions (Tuberculous pleural effusion, TPE) require invasive examinations, whereas patients with cardiogenic pleural effusions (HF) often do not need invasive examinations, but only systemic treatments. Therefore, timely and accurate identification of the etiology of PE is critical to optimizing patient treatment, improving patient quality of life and prognosis. The sensitivity and specificity of the traditional biochemical and immunological methods for detecting NT-proBNP for diagnosing HF are about 90%, but the accuracy of diagnosing HF by the NT-proBNP is influenced by factors such as age, renal function and the like. Metabonomics is the qualitative and quantitative analysis of all small molecule metabolites in organisms, and mainly researches the changes of the types and the amounts of the metabolites after the organisms are stimulated by internal and external factors. The combination of metabonomics and bioinformatics has been a deep search for disease mechanisms, diagnostic markers and drug therapeutic target screening. The LC-MS/MS has the characteristics of high flux, high sensitivity, high specificity and the like, and is more beneficial to identification and screening of diagnostic markers. Acyl carnitines (ACYLCARNITINE, AC) are fatty acid metabolites that can be used as important diagnostic indicators of fatty acid dysoxidation, such as screening for neonatal inherited metabolic diseases. The carbon chain length of C13-C20 in AC is defined as long chain acyl carnitine (LCAC-CHAIN ACYLCARNITINE), and the biological function of LCAC is to transport long chain fatty acids to mitochondria. However, it is not known whether LCAC can be used to aid in diagnosing HF. It should be noted that the information disclosed in the above background section is only for enhancing understanding of the background of the invention and thus may include information that does not form the prior art that is already known to those of ordinary skill in the art. Disclosure of Invention In order to solve the problems in the prior art, the invention provides a biomarker combination for screening heart failure pleural effusion, and application, a system, equipment and a medium thereof. The technical problems to be solved by the invention are realized by the following technical scheme: In a first aspect, the present invention provides a biomarker combination for screening heart failure pleural effusion, the biomarker combination being selected from at least one of the following (a) - (d): (a) The ratio of the concentration of palmitoyl carnitine in the hydrothorax sample to the concentration of palmitoyl carnitine in the serum sample; (b) The ratio of the concentration of stearoyl carnitine in the hydrothorax sample to the concentration of stearoyl carnitine in the serum sample; (c) The ratio of the concentration of octadecadienoyl carnitine in the hydrothorax sample to the concentration of octadecadienoyl carnitine in the serum sample; (d) Ratio of the concentration of octadecenoyl carnitine in the hydrothorax sample to the concentration of octadecenoyl carnitine in the serum sample. In a second aspect, the invention provides an application of the detection reagent for screening biomarker combinations of heart failure pleural effusion in preparation of products for screening heart failure pleural effusion. In one embodiment of the invention, the product is a kit for screening heart failure pleural effusion, comprising a first detection reagent for detecting palmitoyl carnitine concentration in a pleural fluid sample and a serum sample; And/or a second detection reagent for detecting the concentration of stearoyl carnitine in a hydrothorax sample and a serum sample; And/or a third detection reagent for detecting the concentration of octadecadienoyl carnitine in a hydrothorax sample and a serum sample; And/or a fourth detection reagent for detecting the concentration of octadecenoyl carnitine in a hydrothorax sample and a serum sample. In a third aspect, the present invention provides a system for screening for heart failure pleural effusion, comprising: The data acquisition module is used